From: Proceedings of the 27th European Paediatric Rheumatology Congress (PReS 2021)
 | Range | 26/04/2017 | 19/02/2018 | 13/06/2018 | 24/02/2020 | 08/04/2020 | 22/04/2021 |
---|---|---|---|---|---|---|---|
 |  | Onset primary HLH | Remission after emapalumab | Onset of liver involvement | sJIA critria and full-blown MAS | Start emapalumab | 1 year after emapalumab |
GB (10^3 /uL) | 5.5-15 | 12,27 | 6,44 | 6,09 | 7,48 | 0,91 | 4,8 |
PLT (10^3 /uL) | 150-450 | 46 | 438 | 206 | 64 | 11 | 207 |
Ferritin (ng/ml) | 13-150 | 293.400 | 100 | 27 | 3.460 | 13.411 | 5 |
AST (UI/L) | <32 | 578 | 31 | 851 | 733 | 432 | 32 |
IL-18 (pg/ml) | <300 | >125.000 | 24.470 | 41.399 | 51.510 | 50.000 | 12.370 |
CXCL9 (pg/ml) | <612 | 379.642 | 710 | 546 | 15.163 | 193.783 | <50 |
Neopterin (ng/ml) | <2,5 | 11,05 | 2,97 | 4,20 | 16,3 | 8,9 | 0,75 |